COMPARATIVE ANALYSIS BETWEEN GROWTH FACTORS OF EPIPHYSEAL PLATE (SOX-5, SOX-9, RUNX-2, IHH, PTHrP) AND EXPRESSION OF APOPTOTIC MODULATION FACTOR (BCL-2) IN BENIGN AND MALIGNANT CARTILAGINOUS TUMORS. CORRELATION WITH CLINICAL AND AND MORPHOLOGICAL FINDINGS

• Grant number: 15/06639-9
• Support Opportunities: Regular Research Grants
• Start date: October 01, 2015
• End date: September 30, 2017
• Field of knowledge: Health Sciences - Medicine - Pathological Anatomy and Clinical Pathology
• Principal Investigator: Eliane Maria Ingrid Amstalden
• Grantee: Eliane Maria Ingrid Amstalden
• Host Institution: Faculdade de Ciências Médicas (FCM). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil

Abstract

The chondrosarcomas (CS) are a heterogeneous group of tumors with different clinical and morphological manifestations. The distinction between grade I chondrosarcoma and enchondroma is difficult. It is necessary to find more precise parameters to assist in diagnosis, histological graduation and prognosis of CS and therefore its treatment. Some cartilaginous tumors have morphological similarities with epiphyseal plate as: mesenchymal chondrosarcoma with the immature or rest phase; enchondroma and conventional chondrosarcomas with proliferative chondrocytes and clear cell chondrosarcoma with hypertrophic phase cells of the epiphyseal plate. Growth and modulation factors interact with chondral cells at different stages of maturation of the plate. Some of these factors act stimulating (SOX-5; SOX-9; Runx-2; Ihh; PTHrP and BCL-2) and modulating (SOX-5) the growth plate. Probably they have some association with the cartilaginous tumors however their relationship has not been well explored yet. The aim of this project is to evaluate the expression of these molecules of growth plate with the cartilaginous tumors; correlating with: histological grade; clinical and outcome data. Cartilaginous tumors cases will be collected from Pathology department archives (Clinical Hospital of FCM/UNICAMP and Federal University of Parana). The tumors will be reclassified and graded according to WHO criteria (2013). The molecular analyses will be evaluated by immunohistochemistry method. The results will be correlated each other, and compared with clinical and patients outcome. A statistical test will be submitted for evaluate the significant values. (AU)